查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
2017-2027年肿瘤学流式细胞术市场 - 全球行业规模、份额、趋势、机会及预测，按组件、按技术、按适应症、按应用、按最终用户、按公司和按地区细分
市场调查报告书
商品编码
1303138

2017-2027年肿瘤学流式细胞术市场 - 全球行业规模、份额、趋势、机会及预测，按组件、按技术、按适应症、按应用、按最终用户、按公司和按地区细分

Flow Cytometry in Oncology Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented By Component, By Technology, By Indication, By Application, By End User, By company and By Region
出版日期: | 出版商: TechSci Research | 英文 114 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

预计在2023-2027年的预测期内，全球肿瘤流式细胞仪市场将出现令人瞩目的增长。主要因素包括癌症发病率的增长、流式细胞仪领域的技术演进以及消费者对精准医疗和定制化治疗意识的提高，这些都推动了市场的增长。流式细胞仪是一种基于生物物理和激光的分析技术，用于在激光束的帮助下对悬浮在液体中的细胞或胶束进行评估。该技术有助于对细胞类型进行细分，并利用探针确定疾病的残留程度，从而为患者制定有效的治疗方案。支持市场增长的其他因素包括：癌症诊断领域的快速发展、研发活动的增加、血液恶性肿瘤治疗资金的增加、流式细胞仪应用的增加、癌症相关病例数量的指数级增长、世界人口基数的增加、无机增长战略的不断采用以及慢性疾病的不断出现。

癌症和血液恶性肿瘤发病率上升

流式细胞术用于诊断癌症和检测最低残留水平。肺癌、乳腺癌、胃癌、皮肤癌、咽喉癌和其他血液相关癌症等癌症发病率的上升促进了市场的增长。据世界卫生组织预测，2020年癌症将成为主要死因，全球将有近1000万人死于癌症，即每6人中就有1人死于癌症。最常见的癌症是肺癌、结肠癌、直肠癌、乳腺癌和前列腺癌。此外，白血病、淋巴瘤和骨髓瘤等血液恶性肿瘤患者人数激增，需要流式细胞术诊断和检测残留。根据美国癌症协会的数据，在美国，大约每3分钟就有一人被诊断出患有白血病、淋巴瘤和骨髓瘤。

消费者对定制治疗和精准医疗的认识不断提高

消费者对精准医疗和定制疗法的认识不断提高，促进了市场的增长。医生正在向人们宣传定制治疗和精准医疗的益处。精准医疗在治疗各种癌症方面具有不可估量的巨大潜力，因此促进了市场的增长。此外，政府为提高人们的认识而采取的各种倡议也促进了市场的增长。例如，2015年，美国发起了精准医疗倡议（PMI），该倡议旨在摒弃 "一刀切 "的医疗服务方式，根据人们的独特个性，包括基因、生活方式和生物学特性，采用量身定制的治疗和预防方法。

细胞测量仪器的技术发展将支持市场增长

主要企业越来越重视开发先进的流式细胞仪产品，这些产品操作简便、改进了工作流程并能快速读取数据。由于流式细胞仪的快速发展，采用流式细胞仪进行治疗和监测癌症诊断的人数激增，推动了市场的增长。例如，2018年，默克公司推出了新的Cell Stream台式流式细胞仪系统，这是一款压缩型可定制流式细胞仪，使用摄像头进行检测。通过此次发布，该公司扩展了其流式细胞仪产品线。

可定制产品

根据给定的市场数据，TechSci Research可根据公司的具体需求提供定制服务。报告可提供以下定制选项：

公司信息

  • 其他市场参与者（最多五家）的详细分析和概况。

目录

第一章：产品概述

第二章：研究方法

第三章：执行摘要

第4章：COVID-19对全球肿瘤流式细胞仪市场的影响

第五章：客户之声

第6章：全球肿瘤流式细胞仪市场展望

  • 市场规模与预测
    • 按价值
  • 市场份额及预测
    • 按组成部分（检测和试剂盒、仪器、试剂和耗材、软件）
    • 按技术（基于细胞和基于微珠）
    • 按适应症（血液恶性肿瘤和实体瘤）
    • 按应用（转化研究和临床应用）
    • 按终端用户（医院和诊所、诊断实验室、学术和研究机构、其他）
    • 按地区
    • 按公司（2021年）
  • 市场地图

第七章 : 北美肿瘤流式细胞仪市场前景

  • 市场规模与预测
    • 按价值
  • 市场份额及预测
    • 按组件
    • 按技术分类
    • 按适应症
    • 按应用
    • 按终端用户
    • 按国家
  • 北美：国家分析
    • 美国
    • 美国
    • 加拿大

第八章：欧洲肿瘤流式细胞仪市场前景展望

  • 市场规模与预测
    • 按价值
  • 市场份额及预测
    • 按组件
    • 按技术分类
    • 按适应症
    • 按应用
    • 按终端用户
    • 按国家
  • 欧洲：国家分析
    • 法国
    • 德国
    • 英国
    • 德国
    • 西班牙

第九章 : 亚太地区肿瘤流式细胞仪市场前景展望

  • 市场规模与预测
    • 按价值
  • 市场份额及预测
    • 按组件
    • 按技术分类
    • 按适应症
    • 按应用
    • 按终端用户
    • 按国家
  • 亚太地区国家分析
    • 中国
    • 中国
    • 印度
    • 韩国
    • 澳大利亚

第10章 : 南美肿瘤流式细胞仪市场展望

  • 市场规模与预测
    • 按价值
  • 市场份额及预测
    • 按组件
    • 按技术分类
    • 按适应症
    • 按应用
    • 按终端用户
    • 按国家
  • 南美洲：国家分析
    • 巴西
    • 巴西
    • 哥伦比亚

第十一章 ：中东和非洲肿瘤流式细胞仪市场前景

  • 市场规模与预测
    • 按价值
  • 市场份额及预测
    • 按组件
    • 按技术分类
    • 按适应症
    • 按应用
    • 按终端用户
    • 按国家
  • 中东和非洲：国家分析
    • 南非 流式细胞术在肿瘤学中的应用
    • 沙特阿拉伯 流式细胞术在肿瘤学中的应用
    • 阿联酋 肿瘤学中的流式细胞术
    • 土耳其 肿瘤学流式细胞术
    • 埃及 肿瘤学中的流式细胞术

第十二章 ：市场动态

  • 驱动因素
  • 挑战

第13章 ：市场趋势与发展

第14章：竞争格局

  • 安捷伦科技公司安捷伦技术公司Becton, Dickinson and Company bioAffinity Technologies, Inc.Bio-Rad Laboratories, Inc.Bio-Techne Corporation Cytognos, S.L. Danaher Corporation Miltenyi Biotec B.V. & Co.KG Laboratory Corporation of America Holdings

第十五章：战略建议

简介目录
Product Code: 13126

The global flow cytometry in the oncology market is anticipated to observe impressive growth during the forecast period, 2023-2027. The major factors include growing occurrences of cancer, technological evolution in the field of flow cytometry, and rising consumer awareness for precision medicine and tailored therapy are fueling the growth of the market. Flow cytometry is a biophysical and laser-based analytical technology that is used in the evaluation of cells or micelles that are generally suspended in a fluid with the help of a laser beam. This technique facilitates subclassifying cell types and identifying residual levels of disease using probes to develop an effective treatment plan for the patient. The other factors supporting the market's growth are rapid developments in the field of cancer diagnostics, rise in R&D activities, increasing fund infusions for hematological malignancies, rising adoption of flow cytometry instruments, the exponential rise in the number of cases associated with cancer, rise in world population base, growing adoption of inorganic growth strategies, and increasing emergence of chronic diseases.

Rising Prevalence of Cancer & Hematological Malignancies

Flow cytometry is used to diagnose cancer and detect minimal residue levels. Growing incidences of cancer, such as lung, breast, stomach, skin, throat, and other blood-related cancers, are augmenting the growth of the market. According to WHO, in 2020, cancer is a prominent cause of death, reporting nearly 10 million deaths globally, or nearly one in six deaths. The most common cancers are lung, colon and rectum, breast, and prostate cancers. Also, there is a surge in the number of people suffering from hematological malignancies such as leukemia, lymphoma, and myeloma, which need flow cytometry for the diagnosis and detection of residue. According to the American Cancer Society, in the United States, around every 3 minutes, a person is diagnosed with leukemia, lymphoma, and myeloma.

Growing Consumer Awareness for Tailored Therapy and Precision Medicines

The rising consumer awareness of precision medicine and tailored therapy is bolstering the growth of the market. People are being educated by doctors about the benefits associated with tailored therapy and precision medicine. Precision medicine has invaluable and enormous potential to cure various cancers, thus augmenting the growth of the market. Furthermore, various initiatives by the governments to raise awareness among people are facilitating the growth of the market. For instance, in 2015, The Precision Medicine Initiative (PMI) was launched in the US, an initiative to move away from the "one-size-fits-all" approach to health care delivery and to use tailor treatment and prevention approaches to people's unique individualities, including gene, lifestyle, and biology.

Technological Developments in Cytometry Instruments to Support Market Growth

Rising emphasis of key players on developing advanced flow cytometry products that offer ease in operability, improved workflows, and quick data reading. Owing to the rapid developments in cytometry instruments, the adoption of flow cytometers for therapeutic conducting and monitoring cancer diagnosis is surging, which propels the growth of the market. For instance, in 2018, Merck KGaA launched its new Cell Stream benchtop flow cytometry system, which is a compressed, customizable flow cytometer that uses a camera for detection. With this launch, the company has extended its product line in flow cytometers.

Market Segmentation

The global flow cytometry in the oncology market is segmented into component, technology, indication, application, end user, and company. Based on components, the market is divided into assays & kits, instruments, reagents & consumables, and software. Based on technology, the market is divided into cell-based and bead-based. Based on indication, the market is divided into hematological malignancies and solid tumors. Based on application, the market is divided into translational research and clinical applications. Based on end-user, the market is divided into hospitals & clinics, diagnostic laboratories, academic & research institutions, and others. In terms of country, the United States is expected to be a lucrative market in the forecast period due to rising incidences of cancer and rising advancements in technology in the country.

Market Players

Agilent Technologies, Inc., Apogee Flow Systems Ltd., Becton, Dickinson and Company, bioAffinity Technologies, Inc., Bio-Rad Laboratories, Inc., Bio-Techne Corporation, Cytognos, S.L., Danaher Corporation, Miltenyi Biotec BV & Co. KG, and Laboratory Corporation of America Holdings are some of the leading companies operating in the market.

Report Scope

In this report, global flow cytometry in the oncology market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

Flow Cytometry in Oncology Market, By Component:

  • Assays & Kits
  • Instruments
  • Reagents & Consumables
  • Software

Flow Cytometry in Oncology Market, By Technology:

  • Cell-Based
  • Bead Based

Flow Cytometry in Oncology Market, By Indication:

  • Hematological Malignancies
  • Solid Tumors

Flow Cytometry in Oncology Market, By Application:

  • Translational Research
  • Clinical Applications

Flow Cytometry in Oncology Market, By End User:

  • Hospitals & Clinics
  • Diagnostic Laboratories
  • Academic & Research Institutions
  • Others

Flow Cytometry in Oncology Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • Europe & CIS
    • Germany
    • France
    • United Kingdom
    • Spain
    • Italy
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Egypt
    • Turkey

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global Flow Cytometry in Oncology Market

Available Customizations

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Impact of COVID-19 on Global Flow Cytometry in Oncology Market

5. Voice of Customer

6. Global Flow Cytometry in Oncology Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Component (Assays & Kits, Instruments, Reagents & Consumables, Software)
    • 6.2.2. By Technology (Cell Based v/s Bead Based)
    • 6.2.3. By Indication (Hematological Malignancies v/s Solid Tumors)
    • 6.2.4. By Application (Translational Research v/s Clinical Applications)
    • 6.2.5. By End User (Hospitals & Clinics, Diagnostic Laboratories, Academic & Research Institutions, Others)
    • 6.2.6. By Region
    • 6.2.7. By Company (2021)
  • 6.3. Market Map

7. North America Flow Cytometry in Oncology Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Component
    • 7.2.2. By Technology
    • 7.2.3. By Indication
    • 7.2.4. By Application
    • 7.2.5. By End User
    • 7.2.6. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Flow Cytometry in Oncology Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Component
        • 7.3.1.2.2. By Technology
        • 7.3.1.2.3. By Indication
        • 7.3.1.2.4. By Application
        • 7.3.1.2.5. By End User
    • 7.3.2. Canada Flow Cytometry in Oncology Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Component
        • 7.3.2.2.2. By Technology
        • 7.3.2.2.3. By Indication
        • 7.3.2.2.4. By Application
        • 7.3.2.2.5. By End User
    • 7.3.3. Mexico Flow Cytometry in Oncology Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Component
        • 7.3.3.2.2. By Technology
        • 7.3.3.2.3. By Indication
        • 7.3.3.2.4. By Application
        • 7.3.3.2.5. By End User

8. Europe Flow Cytometry in Oncology Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Component
    • 8.2.2. By Technology
    • 8.2.3. By Indication
    • 8.2.4. By Application
    • 8.2.5. By End User
    • 8.2.6. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. France Flow Cytometry in Oncology Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Component
        • 8.3.1.2.2. By Technology
        • 8.3.1.2.3. By Indication
        • 8.3.1.2.4. By Application
        • 8.3.1.2.5. By End User
    • 8.3.2. Germany Flow Cytometry in Oncology Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Component
        • 8.3.2.2.2. By Technology
        • 8.3.2.2.3. By Indication
        • 8.3.2.2.4. By Application
        • 8.3.2.2.5. By End User
    • 8.3.3. United Kingdom Flow Cytometry in Oncology Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Component
        • 8.3.3.2.2. By Technology
        • 8.3.3.2.3. By Indication
        • 8.3.3.2.4. By Application
        • 8.3.3.2.5. By End User
    • 8.3.4. Italy Flow Cytometry in Oncology Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Component
        • 8.3.4.2.2. By Technology
        • 8.3.4.2.3. By Indication
        • 8.3.4.2.4. By Application
        • 8.3.4.2.5. By End User
    • 8.3.5. Spain Flow Cytometry in Oncology Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Component
        • 8.3.5.2.2. By Technology
        • 8.3.5.2.3. By Indication
        • 8.3.5.2.4. By Application
        • 8.3.5.2.5. By End User

9. Asia-Pacific Flow Cytometry in Oncology Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Component
    • 9.2.2. By Technology
    • 9.2.3. By Indication
    • 9.2.4. By Application
    • 9.2.5. By End User
    • 9.2.6. By Country
  • 9.3. Asia-Pacific: Country Analysis
    • 9.3.1. China Flow Cytometry in Oncology Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Component
        • 9.3.1.2.2. By Technology
        • 9.3.1.2.3. By Indication
        • 9.3.1.2.4. By Application
        • 9.3.1.2.5. By End User
    • 9.3.2. India Flow Cytometry in Oncology Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Component
        • 9.3.2.2.2. By Technology
        • 9.3.2.2.3. By Indication
        • 9.3.2.2.4. By Application
        • 9.3.2.2.5. By End User
    • 9.3.3. Japan Flow Cytometry in Oncology Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Component
        • 9.3.3.2.2. By Technology
        • 9.3.3.2.3. By Indication
        • 9.3.3.2.4. By Application
        • 9.3.3.2.5. By End User
    • 9.3.4. South Korea Flow Cytometry in Oncology Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Component
        • 9.3.4.2.2. By Technology
        • 9.3.4.2.3. By Indication
        • 9.3.4.2.4. By Application
        • 9.3.4.2.5. By End User
    • 9.3.5. Australia Flow Cytometry in Oncology Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Component
        • 9.3.5.2.2. By Technology
        • 9.3.5.2.3. By Indication
        • 9.3.5.2.4. By Application
        • 9.3.5.2.5. By End User

10. South America Flow Cytometry in Oncology Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Component
    • 10.2.2. By Technology
    • 10.2.3. By Indication
    • 10.2.4. By Application
    • 10.2.5. By End User
    • 10.2.6. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Flow Cytometry in Oncology Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Component
        • 10.3.1.2.2. By Technology
        • 10.3.1.2.3. By Indication
        • 10.3.1.2.4. By Application
        • 10.3.1.2.5. By End User
    • 10.3.2. Argentina Flow Cytometry in Oncology Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Component
        • 10.3.2.2.2. By Technology
        • 10.3.2.2.3. By Indication
        • 10.3.2.2.4. By Application
        • 10.3.2.2.5. By End User
    • 10.3.3. Colombia Flow Cytometry in Oncology Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Component
        • 10.3.3.2.2. By Technology
        • 10.3.3.2.3. By Indication
        • 10.3.3.2.4. By Application
        • 10.3.3.2.5. By End User

11. Middle East and Africa Flow Cytometry in Oncology Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Component
    • 11.2.2. By Technology
    • 11.2.3. By Indication
    • 11.2.4. By Application
    • 11.2.5. By End User
    • 11.2.6. By Country
  • 11.3. MEA: Country Analysis
    • 11.3.1. South Africa Flow Cytometry in Oncology Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Component
        • 11.3.1.2.2. By Technology
        • 11.3.1.2.3. By Indication
        • 11.3.1.2.4. By Application
        • 11.3.1.2.5. By End User
    • 11.3.2. Saudi Arabia Flow Cytometry in Oncology Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Component
        • 11.3.2.2.2. By Technology
        • 11.3.2.2.3. By Indication
        • 11.3.2.2.4. By Application
        • 11.3.2.2.5. By End User
    • 11.3.3. UAE Flow Cytometry in Oncology Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Component
        • 11.3.3.2.2. By Technology
        • 11.3.3.2.3. By Indication
        • 11.3.3.2.4. By Application
        • 11.3.3.2.5. By End User
    • 11.3.4. Turkey Flow Cytometry in Oncology Market Outlook
      • 11.3.4.1. Market Size & Forecast
        • 11.3.4.1.1. By Value
      • 11.3.4.2. Market Share & Forecast
        • 11.3.4.2.1. By Component
        • 11.3.4.2.2. By Technology
        • 11.3.4.2.3. By Indication
        • 11.3.4.2.4. By Application
        • 11.3.4.2.5. By End User
    • 11.3.5. Egypt Flow Cytometry in Oncology Market Outlook
      • 11.3.5.1. Market Size & Forecast
        • 11.3.5.1.1. By Value
      • 11.3.5.2. Market Share & Forecast
        • 11.3.5.2.1. By Component
        • 11.3.5.2.2. By Technology
        • 11.3.5.2.3. By Indication
        • 11.3.5.2.4. By Application
        • 11.3.5.2.5. By End User

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

14. Competitive Landscape

  • 14.1. Agilent Technologies, Inc.
  • 14.2. Apogee Flow Systems Ltd.
  • 14.3. Becton, Dickinson and Company
  • 14.4. bioAffinity Technologies, Inc.
  • 14.5. Bio-Rad Laboratories, Inc.
  • 14.6. Bio-Techne Corporation
  • 14.7. Cytognos, S.L.
  • 14.8. Danaher Corporation
  • 14.9. Miltenyi Biotec B.V. & Co. KG
  • 14.10. Laboratory Corporation of America Holdings

15. Strategic Recommendations